Partners 2022

Gold Partners

Hansa Biopharma

www.hansabiopharma.com

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

This conditional approval was also granted by the MHRA in January 2021.
Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.


Astellas Pharma Limited

www.astellas.eu

On the forefront of healthcare change, Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.

Astellas Pharma is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. We strive to develop therapies that are first-in-class and best-in-class. Treatments that offer patients and their doctors genuinely new options for improving care.


Sandoz

www.sandoz.uk.com

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercialising affordable medicines. In 2020, we saved the NHS an estimated £1.2 billion through the provision of generic and biosimilar alternatives to patented medicines. With our broad portfolio of medicines, we reach approximately 421,000 patients per month 1.

Our ambition is to establish Sandoz UK as the leading partner to deliver exceptional value for our customers and patients.

 1 Sandoz Fast Facts – 2020 (September 2021 | 158909)

Silver Partners

Chiesi Limited

www.chiesi.uk.com

Chiesi Limited are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Special Care and Rare Diseases.

Transplantation is an area to which Chiesi are committed to developing further as part of a growing Special Care portfolio.

Chiesi are proud to play a part in helping patients protect their gift of life, and aim to be an important, reliable partner for transplant clinicians and patient organisations across the UK

UK-TR-2200001 January 2022

Takeda

www.takeda.com/en-gb

Takeda Pharmaceutical Company Limited is headquartered in Japan and is a global, values-based, R&D-driven biopharmaceutical leader. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. Our employees are committed to improving quality of life for patients.

Additional information about Takeda UK Ltd. is available through its corporate website